跳至主要内容
临床试验/NCT04172480
NCT04172480Unknown不适用

HUSH Restriction in HIV Infected Patients

ANRS, Emerging Infectious Diseases3 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2019年10月1日最近更新:
适应症

试验速览

阶段
不适用
入组人数
50
试验地点
3
主要终点
Viremia

研究概览

简要总结

HIV eradication faces a major obstacle that is viral persistence in latent reservoir cells despite antiretroviral therapy. Epigenetic repression plays a central role in viral transgene latency and several epigenetic regulators have been involved in this process. Among them, the "Human Silencing Hub" or HUSH complex, composed of Tasor, MPP8 and periphilin, has been shown to recruit the H3K9me3 methyltransferase "SET domain bifurcated 1" (SETDB1) and is therefore responsible for genes' epigenetic repression. Our recent results highlight the ability of Vpx from HIV-2/SIVsmm to counteract HUSH and to reactivate latent viruses in a latency model. We propose here to study HUSH activity along pathogenesis.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
15 Years 至 80 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Viremia

时间窗: Baseline

Intracellular HIV RNA load expressed in number of copies / ml

Total HIV DNA and integrated HIV DNA

时间窗: Baseline

Quantification by qPCR

Hush activity

时间窗: Baseline

Transcription rate of cellular genes targeted by HUSH by qRT-PCR

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验